Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Kymera Therapeutics (NASDAQ: KYMR) will announce topline results from the BroADen Phase 1b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, on Monday, December 8, 2025.

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) will announce topline results from the BroADen Phase 1b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis, on Monday, December 8, 2025.

A press release will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. A replay and presentation will be available after the event. Investors can register via the company website at www.kymeratx.com under News and Events.

Argus Dec 8 session

+41.55% close to close Open Argus

Details

News Market Reaction – KYMR

On Dec 8, the first trading day after this news, KYMR closed 41.55% above the previous close.

Data tracked by StockTitan Argus for the Dec 8 session.

Key Figures

BroADen readout date: December 8, 2025 Current share price: $66.56 52-week high: $68.80 +5 more

BroADen readout date

December 8, 2025

Phase 1b KT-621 atopic dermatitis trial results timing

Current share price

$66.56

Price before Phase 1b readout announcement

52-week high

$68.80

Shares trading modestly below 52-week high pre-readout

Cash balance

$978.7M

Cash, cash equivalents and marketable securities as of Sep 30, 2025 (10-Q)

Q3 2025 net loss

$82.175M

Net loss in Q3 2025 per 10-Q

Q3 2025 R&D expense

$74.094M

Research and development expense in Q3 2025

Follow-on offering proceeds

$288.4M

Aggregate gross proceeds from June–July 2025 follow-on offering

Potential Sanofi milestones

$975M

Future development, regulatory and commercial milestones under IRAK4 collaboration

Historical Context

5 past events · Latest: Nov 25

5 events

1. Nov 25

   Clinical trial start

   24h Move

   +0.7%

   First patient dosed in BROADEN2 Phase 2b KT-621 AD trial.

2. Nov 24

   Investor conferences

   24h Move

   -0.7%

   Participation in multiple December investor fireside chats.

3. Nov 04

   Earnings and pipeline

   24h Move

   +0.3%

   Q3 2025 results with strong cash and KT-621 clinical progress.

4. Nov 03

   Investor conferences

   24h Move

   -3.4%

   Expanded November conference schedule and webcast availability.

5. Oct 28

   Earnings date

   24h Move

   +1.8%

   Announcement of Q3 2025 earnings release date and call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1b, atopic dermatitis, stat6, oral small molecule degrader, +1 more

5 terms

phase 1b medical

"results from the BroADen Phase 1b clinical trial evaluating KT-621"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

atopic dermatitis medical

"in patients with moderate to severe atopic dermatitis (AD)"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

stat6 medical

"KT-621, its oral STAT6 degrader, in patients with moderate"

STAT6 is a protein inside cells that acts like a messenger and switch, carrying signals from the cell surface to turn specific genes on. It is central to immune responses linked to allergies, asthma and some cancers, so changes in STAT6 activity or drugs that affect it can signal potential clinical benefits or risks. Investors watch STAT6 when it appears as a drug target or biomarker because it can influence the value and prospects of therapies in development.

oral small molecule degrader medical

"advancing a new class of oral small molecule degrader medicines"

An oral small molecule degrader is a pill-form drug that binds to a specific disease-related protein and sends it to the cell’s natural disposal system so the protein is broken down and removed. For investors, these drugs represent a different way to tackle targets that were hard to block with traditional drugs, so successful clinical results can change a company’s prospects quickly—think of swapping a bandage for a vacuum that removes the root cause.

webcast technical

"A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025

WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase 1b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, December 8, 2025. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be available following the event. 

About KT-621
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. In the Phase 1 clinical study in healthy volunteers, KT-621 demonstrated complete STAT6 degradation in blood and skin following low daily oral doses, reductions of multiple disease relevant Type 2 biomarkers, and a safety profile undifferentiated from placebo. KT-621, the first STAT6-directed drug to enter clinical evaluation, has the potential to transform treatment paradigms for more than 130 million patients around the world, including children and adults, suffering from Type 2 diseases such as atopic dermatitis (AD), asthma, bullous pemphigoid (BP), chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), and prurigo nodularis (PN), among others.

The Company’s KT-621 BROADEN2 Phase 2b trial in moderate to severe AD patients is ongoing, and patient dosing has commenced. Data is expected to be reported by mid-2027. The BREADTH Phase 2b trial in asthma is planned to start in the first quarter of 2026. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Type 2 dermatology, gastroenterology and respiratory indications.

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn. 

Investor and Media Contact: 
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Kymera (NASDAQ: KYMR) release BroADen Phase 1b KT-621 results?

Kymera will issue a press release with results on December 8, 2025 at 7:00 a.m. ET.

What time is the Kymera KT-621 webcast and how can I join on December 8, 2025?

The video conference call and webcast start at 8:00 a.m. ET; register or view via www.kymeratx.com News and Events.

What is KT-621 and which condition was it tested for in BroADen Phase 1b?

KT-621 is an oral STAT6 degrader evaluated in patients with moderate to severe atopic dermatitis.

Will Kymera provide a replay or presentation from the December 8, 2025 event?

Yes. A replay of the webcast and a copy of the presentation will be available after the event on the company website.

Where can investors find regulatory or follow-up details after Kymera's KT-621 announcement?

Investors should check the company News and Events page on www.kymeratx.com for the press release, webcast replay, and any follow-up disclosures.